An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
VERDICT
The label
Accumulation
read at $57.24
Ionis Pharmaceuticals Inc holds its Accumulation at $57.24.
PHPhase · the trend structure carries the Accumulation label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · does not pass the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-08-14
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 170 days
Price
$57.24
Valuation
N/A trailing · -49.34 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.40
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$57.24
N/A P/E · -49.34 fwd
Our fair value
$90.00
57% discount
Analyst target (avg)
$90.00
+57% to current
Target low $66.00Analyst target rangeTarget high $115.00
▲ current $57.24 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$57.24
you are here
Conservative
$66.00
+15%
Analyst avg
$90.00
+57%
Our fair value
$90.00
+57%
Analyst high
$115.00
+101%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
-40.70%
Profit margin
-64.66%
Debt to equity
497.80
Analyst consensus
Buy · 21 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company is excluded by both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. It fails on both:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✗ DOES NOT PASS
Why it fails. The problem is its debt ratio. Because both standards agree on this, it is a clear exclusion, not a borderline case.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is 58.6% of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashInterest-bearing cash and securities are 65.4% of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is 12.4% of assets, under the 49% limit.Pass
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
RNA drug maker still deep in the red
Picture a lab turning out targeted RNA therapies that could tackle rare diseases, only for the company to keep burning cash at a fierce rate. Ionis shows eye-catching 87% revenue growth from its commercial-stage medicines, yet posts a negative 31% profit margin and negative 68% ROE. The narrow moat and forward P/E of minus 47.7x leave little room for error in a field where one failed trial can reset everything.
We pass because the opportunity rating sits at none despite the 67% gap to fair value. High growth has not translated into sustainable profits or returns, and a narrow moat offers scant protection against bigger players or regulatory setbacks. Analyst targets cluster at the same fair value, but that does not change the underlying cash losses.
Execution risk in biotech remains brutal, with currency swings and trial outcomes able to wipe out years of progress in months. The ethical screen clears, yet the numbers still flag a business that has yet to prove it can deliver consistent returns. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in IONS's space worth a look
Screened names in the same industry · explore each on its own page.
TRADER
The trader read · the latest dated commentary
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 27.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 99%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (23 analysts) rates it buy, with a mean price target of $105. Entered 2026-08-02 · Distribution
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 27.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 99%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (23 analysts) rates it buy, with a mean price target of $105.
2026-07-18Markdown$73.28+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 99%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (23 analysts) rates it buy, with a mean price target of $105.
2026-07-03Markdown$73.28+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markdown$73.28Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
POLITICAL
The political ledger · congressional disclosures
Disclosures naming IONS
Date
Politician
Party
Type
Amount
8 May2024
Tommy Tuberville
Republican
sell
1K–15K
6 May2026
Ro Khanna
Democrat
sell
1K–15K
3 May2024
Tommy Tuberville
Republican
sell
1K–15K
27 May2026
Ro Khanna
Democrat
buy
1K–15K
27 Mar2026
Alan Armstrong
Republican
buy
1K–15K
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$75.38
-3.0%
·
$971
-3.0%
2 months
$75.17
-2.7%
·
$973
-2.7%
3 months
$72.34
+1.1%
·
$1,011
+1.1%
6 months
$79.14
-7.6%
·
$924
-7.6%
1 year
$36.84
+98.6%
·
$1,986
+98.6%
2 years
$39.79
+83.9%
·
$1,839
+83.9%
3 years
$40.65
+80.0%
·
$1,800
+80.0%
5 years
$37.93
+92.9%
·
$1,929
+92.9%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever IONS does next, these words stay.
Ionis Pharmaceuticals Inc · IONS · Accumulation · $57.24
Recorded 2026-08-14 · before the outcome · scored mechanically
